文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

重组人白细胞介素-1受体拮抗剂对脓毒症的死亡率获益因基线血浆白细胞介素-1受体拮抗剂浓度而异

Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration.
PubMed 文献 · Crit Care Med · 2018-01-01
一句话结论一项随机对照试验的回顾性亚组分析提示,基线血浆白细胞介素-1受体拮抗剂高于2071 pg/mL的脓毒症患者使用重组人白细胞介素-1受体拮抗剂72小时可能降低28天死亡率。

该研究为一项多中心随机对照试验的回顾性亚组分析,纳入529例伴有低血压或低灌注的脓毒症患者(占原试验人群59%),随机接受安慰剂或重组人白细胞介素-1受体拮抗剂治疗72小时。按基线血浆白细胞介素-1受体拮抗剂浓度分层后,重组人白细胞介素-1受体拮抗剂的疗效存在显著异质性(十分位分组交互作用P=0.046,二分类交互作用P=0.028)。基线血浆白细胞介素-1受体拮抗剂高于2071 pg/mL者(n=283)接受重组人白细胞介素-1受体拮抗剂后校正死亡率从45.4%降至34.3%(校正风险差-0.12,95%CI -0.23至-0.01,P=0.044);低于2071 pg/mL者死亡率未降低(校正风险差+0.07,95%CI -0.04至+0.17,P=0.230)。基线血浆白细胞介素-1β浓度与治疗的交互作用无统计学意义。作者认为,针对血浆白细胞介素-1受体拮抗剂高的脓毒症患者开展精准临床试验可能值得考虑。

要点

  • 基线血浆白细胞介素-1受体拮抗剂高于2071 pg/mL的脓毒症患者(n=283)接受重组人白细胞介素-1受体拮抗剂72小时后,校正28天死亡率从45.4%降至34.3%(校正风险差-0.12,95%CI -0.23至-0.01,P=0.044)。
  • 基线血浆白细胞介素-1受体拮抗剂低于2071 pg/mL者使用重组人白细胞介素-1受体拮抗剂后死亡率未降低(校正风险差+0.07,95%CI -0.04至+0.17,P=0.230)。
  • 重组人白细胞介素-1受体拮抗剂疗效按基线血浆白细胞介素-1受体拮抗剂浓度分层存在显著异质性:十分位分组交互作用P=0.046,二分类交互作用P=0.028,且在不同预测死亡率水平间交互作用仍存在。
  • 基线血浆白细胞介素-1β浓度与重组人白细胞介素-1受体拮抗剂治疗的交互作用无统计学意义。
  • 作者认为,针对血浆白细胞介素-1受体拮抗剂高的脓毒症患者开展重组人白细胞介素-1受体拮抗剂的精准临床试验可能值得考虑。

适用人群与场景

  • 529例脓毒症伴低血压或低灌注患者,占原随机对照试验人群的59%。
  • 来源于北美和欧洲的多中心临床试验人群。

诊断标准与关键阈值

  • 以基线血浆白细胞介素-1受体拮抗剂2071 pg/mL为二分类界值:高于2071 pg/mL(n=283)与低于2071 pg/mL两组。

处置流程与药物剂量

  • 随机分配接受安慰剂或重组人白细胞介素-1受体拮抗剂治疗72小时。

研究设计与关键结果

  • 研究类型:多中心随机对照试验的回顾性亚组分析;样本量529例;人群为脓毒症伴低血压或低灌注患者;干预为随机分配安慰剂或重组人白细胞介素-1受体拮抗剂72小时;主要终点为28天死亡率。
  • 基线血浆白细胞介素-1受体拮抗剂高于2071 pg/mL者(n=283):重组人白细胞介素-1受体拮抗剂组校正死亡率34.3% vs 安慰剂组45.4%,校正风险差-0.12(95%CI -0.23至-0.01),P=0.044。
  • 基线血浆白细胞介素-1受体拮抗剂低于2071 pg/mL者:重组人白细胞介素-1受体拮抗剂未降低死亡率,校正风险差+0.07(95%CI -0.04至+0.17),P=0.230。
  • 按血浆白细胞介素-1受体拮抗剂十分位分组交互作用P=0.046,二分类交互作用P=0.028;交互作用在不同预测死亡率水平间仍存在。
  • 血浆白细胞介素-1β浓度与重组人白细胞介素-1受体拮抗剂治疗的交互作用无统计学意义。

证据类型、等级与局限

  • 证据类型:随机对照试验的回顾性亚组分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,针对血浆白细胞介素-1受体拮抗剂高的脓毒症患者开展重组人白细胞介素-1受体拮抗剂的精准临床试验可能值得考虑。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: Plasma interleukin-1 beta may influence sepsis mortality, yet recombinant human interleukin-1 receptor antagonist did not reduce mortality in randomized trials. We tested for heterogeneity in the treatment effect of recombinant human interleukin-1 receptor antagonist by baseline plasma interleukin-1 beta or interleukin-1 receptor antagonist concentration.

DESIGN: Retrospective subgroup analysis of randomized controlled trial.

SETTING: Multicenter North American and European clinical trial.

PATIENTS: Five hundred twenty-nine subjects with sepsis and hypotension or hypoperfusion, representing 59% of the original trial population.

INTERVENTIONS: Random assignment of placebo or recombinant human interleukin-1 receptor antagonist × 72 hours.

MEASUREMENTS AND MAIN RESULTS: We measured prerandomization plasma interleukin-1 beta and interleukin-1 receptor antagonist and tested for statistical interaction between recombinant human interleukin-1 receptor antagonist treatment and baseline plasma interleukin-1 receptor antagonist or interleukin-1 beta concentration on 28-day mortality. There was significant heterogeneity in the effect of recombinant human interleukin-1 receptor antagonist treatment by plasma interleukin-1 receptor antagonist concentration whether plasma interleukin-1 receptor antagonist was divided into deciles (interaction p = 0.046) or dichotomized (interaction p = 0.028). Interaction remained present across different predicted mortality levels. Among subjects with baseline plasma interleukin-1 receptor antagonist above 2,071 pg/mL (n = 283), recombinant human interleukin-1 receptor antagonist therapy reduced adjusted mortality from 45.4% to 34.3% (adjusted risk difference, -0.12; 95% CI, -0.23 to -0.01), p = 0.044. Mortality in subjects with plasma interleukin-1 receptor antagonist below 2,071 pg/mL was not reduced by recombinant human interleukin-1 receptor antagonist (adjusted risk difference, +0.07; 95% CI, -0.04 to +0.17), p = 0.230. Interaction between plasma interleukin-1 beta concentration and recombinant human interleukin-1 receptor antagonist treatment was not statistically significant.

CONCLUSIONS: We report a heterogeneous effect of recombinant human interleukin-1 receptor antagonist on 28-day sepsis mortality that is potentially predictable by plasma interleukin-1 receptor antagonist in one trial. A precision clinical trial of recombinant human interleukin-1 receptor antagonist targeted to septic patients with high plasma interleukin-1 receptor antagonist may be worthy of consideration.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Meyer NJ, Reilly JP, Anderson BJ, et al. Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration. Crit Care Med. 2018. PMID: 28991823. doi:10.1097/CCM.0000000000002749

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。